药理学研究与展望 SCIE

期刊简介预计审稿时间： 20 Weeks

PR&P is jointly published by the American Society for Pharmacology and Experimental Therapeutics (ASPET), the British Pharmacological Society (BPS), and Wiley. PR&P is a bi-monthly open access journal that publishes a range of article types, including: target validation (preclinical papers that show a hypothesis is incorrect or papers on drugs that have failed in early clinical development); drug discovery reviews (strategy, hypotheses, and data resulting in a successful therapeutic drug); frontiers in translational medicine (drug and target validation for an unmet therapeutic need); pharmacological hypotheses (reviews that are oriented to inform a novel hypothesis); and replication studies (work that refutes key findings [failed replication] and work that validates key findings). PR&P publishes papers submitted directly to the journal and those referred from the journals of ASPET and the BPS

PR&P 由美国药理学和实验治疗学会 (ASPET)、英国药理学学会 (BPS) 和 Wiley 联合出版。PR&P 是一份双月刊的开放获取期刊，出版各种类型的文章，包括：靶标验证（表明假设不正确的临床前论文或关于在早期临床开发中失败的药物的论文）；药物发现评论（导致成功治疗药物的策略、假设和数据）；转化医学前沿（针对未满足的治疗需求的药物和靶标验证）；药理学假设（旨在为新假设提供信息的评论）；以及复制研究（反驳关键发现 [复制失败] 的工作和验证关键发现的工作）。PR&P 发表直接提交给期刊的论文以及 ASPET 和 BPS 期刊推荐的论文

《Pharmacology Research & Perspectives》(药理学研究与展望)编辑部通讯方式为THE ATRIUM, SOUTHERN GATE, CHICHESTER, ENGLAND, W SUSSEX, PO19 8SQ。如果您需要协助投稿或润稿服务，您可以咨询我们的客服老师。我们专注于期刊投稿服务十年，熟悉发表政策，可为您提供一对一投稿指导，避免您在投稿时频繁碰壁，节省您的宝贵时间，有效提升发表机率，确保SCI检索（检索不了全额退款）。我们视信誉为生命，多方面确保文章安全保密，在任何情况下都不会泄露您的个人信息或稿件内容。